I agree with what you're saying - it's really quite an amateurish error and is not a good look for Kintor. But to me it seemed like Pigeon was implying that they produced an ineffective drug, which is simply impossible to tell from their (lack of) results.Pigeon is right in the essence of what he is trying to say. It's not about the trial being invalid, it's about the fact that the patients who were recruited for the phase 3 trial weren't screened properly. You can't be in the research field and want to be considered a reputable company and be making "mistakes" like that. It could be interpreted that they tried to con their way through the trial by selecting patients who had a better chance of recovery. The 80% share price drop speaks for itself and big money surely knows that too.
I want Kintors treatments to work as much as every optimistic person here, but I believe we should all exercise caution too.